XML 32 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements Of Cash Flows (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2011
Dec. 31, 2010
Dec. 31, 2009
Operating activities      
Net loss $ (16,982) $ (16,911) $ (24,135)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 922 853 866
Stock-based compensation 1,850 1,828 2,046
Gain from revaluation of warrant liability (486) (39) (63)
Loss (gain) on sale of fixed assets (114) 46 102
Impairment of long-term investment in related party 0 0 2,340
Gain from operating settlement 0 0 (1,381)
Gain on non-controlling equity interest 0 (315) 0
Non-cash interest expense 5 152 0
Changes in operating assets and liabilities, net of effects of acquired business:      
Accounts receivable (1,304) (1,167) 696
Inventories (487) 2,020 3,402
Other assets (13) 99 97
Accounts payable 1,450 (1,193) 102
Accrued restructuring 0 (113) 113
Accrued liabilities (336) 569 1,368
Deferred revenue (137) (97) (100)
Net cash used in operating activities (15,632) (14,268) (14,547)
Investing activities      
Purchases of furniture, equipment and leasehold improvements (158) (1,692) (191)
Sales (purchases) of certain other assets 55 (11) 37
Purchases of investments 0 0 (499)
Sales of investments 0 88 499
Maturities of investments 666 1,545 9,477
Net cash provided by (used in) investing activities 563 (70) 9,323
Financing activities      
Net proceeds from equity incentive plans 143 370 78
Net proceeds from public offering 9,273 19,291 12,135
Proceeds from landlord provided leasehold incentives 0 1,561 0
Proceeds from revolving line of credit 2,300 0 0
Proceeds from debt, net of discount 4,910 4,811 0
Payments on debt and landlord provided leasehold incentives (5,008) (34) (5)
Net cash provided by financing activities 11,618 25,999 12,208
Net increase (decrease) in cash and cash equivalents (3,451) 11,661 6,984
Cash and cash equivalents, beginning of period 28,948 17,287 10,303
Cash and cash equivalents, end of period 25,497 28,948 17,287
Supplemental disclosures:      
Common stock issued in connection with the acquisition of certain assets of BioOne 0 3,423 0
Cash paid for interest $ 1,024 $ 600 $ 4